{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:05:18Z","timestamp":1789488318940,"version":"build-2803163510"},"reference-count":24,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long\u2010term clinical data evaluating oncological outcomes and patient\u2010reported quality of life (QOL) after combining celecoxib with radiotherapy are lacking. Therefore, we aimed to assess oncological outcomes and QOL with extended follow\u2010up to determine the effect of celecoxib combined with low\u2010dose\u2010rate brachytherapy (LDR\u2010BT) in the present study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      An open\u2010label, randomized study was conducted to evaluate the effect of COX\u20102 inhibitors, specifically celecoxib, on preventing acute genitourinary system toxicity between May 2010 and July 2013, with a negative result for the primary endpoint. In the control group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009156), tamsulosin was administered at 0.2\u2009mg\/day for 6 months, and in the celecoxib group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009154), tamsulosin at 0.2\u2009mg\/day for 6 months was combined with celecoxib at 200\u2009mg\/day for 3 months. Oncological outcomes and QOL (Expanded Prostate Cancer Index Composite) were compared between the two groups in this post hoc extended follow\u2010up analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median follow\u2010up time after LDR\u2010BT was 120 months (interquartile range, 98\u2010134 months). The cumulative incidences of biochemical recurrence (BCR) and metastasis were significantly lower in the celecoxib group than those in the control group (10\u2010year cumulative incidence of BCR: 1.5% vs 9.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006; 10\u2010year cumulative incidence of metastasis: 0% vs 5.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). There were no significant differences between the two groups in prostate cancer\u2010specific survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.06) or overall survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.64). Regarding QOL, there was no significant difference between the two groups in score changes before treatment in the urinary, bowel, sexual, or hormonal domain at 24, 36, 48, 60, or 120 months after LDR\u2010BT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Celecoxib combined with LDR\u2010BT for prostate cancer was associated with lower cumulative incidence of BCR and metastasis, although QOL impairment was not ameliorated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>UMIN000003649.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pros.70136","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T19:18:52Z","timestamp":1769109532000},"page":"683-688","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Celecoxib Combined With Low\u2010Dose\u2010Rate Brachytherapy on Long\u2010Term Oncological Outcomes and Quality of Life in Prostate Cancer: Post Hoc Analysis of an Open\u2010Label Controlled Randomized Trial"],"prefix":"10.1002","volume":"86","author":[{"given":"Yasushi","family":"Nakai","sequence":"first","affiliation":[{"name":"Department of Urology Nara Medical University Kashihara Nara Japan"},{"name":"Department of Prostate Brachytherapy Nara Medical University Kashihara Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Urology Nara Medical University Kashihara Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Asakawa","sequence":"additional","affiliation":[{"name":"Department of Prostate Brachytherapy Nara Medical University Kashihara Nara Japan"},{"name":"Department of Radiation Oncology Nara Medical University Kashihara Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-7356","authenticated-orcid":false,"given":"Makito","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of Urology Nara Medical University Kashihara Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Yamaki","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Nara Medical University Kashihara Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Isohashi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Nara Medical University Kashihara Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Urology Nara Medical University Kashihara Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9242-7877","authenticated-orcid":false,"given":"Nobumichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Prostate Brachytherapy Nara Medical University Kashihara Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.11.018"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.11.026"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0587"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rry101"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.498"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3010342"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2017.12.004"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.5114\/jcb.2019.88142"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.06.014"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70280-2"},{"key":"e_1_2_13_12_1","first-page":"2998","article-title":"A Selective cyclooxygenase\u20102 Inhibitor, NS\u2010398, Enhances the Effect of Radiation in Vitro and In Vivo Preferentially on the Cells That Express Cyclooxygenase\u20102","volume":"7","author":"Pyo H.","year":"2001","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.01.019"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-13-1"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1950"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14294"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)00631-X"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.06.037"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2024.09.003"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70088-8"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2067"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prnil.2019.10.004"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871523017666180411162114"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-1-9"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.70136","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pros.70136","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.70136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:31:44Z","timestamp":1789486304000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.70136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/pros.70136"],"URL":"https:\/\/doi.org\/10.1002\/pros.70136","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"2025-11-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}